Cite
HARVARD Citation
Xia, L. et al. (2022). Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. Journal for immunotherapy of cancer. 10 (1), p. . [Online].